Sinotherapeutics (SH:688247) Ge Long Hui A P P·2026-02-27 08:21Core Viewpoint - Xuantai Pharmaceutical (688247.SH) reported a significant decline in both revenue and net profit for the year 2025, primarily due to ongoing domestic drug procurement policies and increased competition in overseas markets [1] Financial Performance - The company achieved total operating revenue of 446.49 million yuan, a year-on-year decrease of 12.73% [1] - The net profit attributable to the parent company was 48.95 million yuan, down 61.67% year-on-year [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 31.38 million yuan, reflecting a 72.47% year-on-year decline [1] Market Challenges - Domestic drug procurement policies have led to significant price reductions for some products, resulting in narrowed profit margins [1] - In overseas markets, increased industry competition and adjustments in tariff policies have caused a decline in both sales and profitability of related products [1] Impairment Losses - The company has prudently recognized impairment losses on accounts receivable, inventory, goodwill, and other assets in accordance with relevant accounting standards, negatively impacting the current net profit [1]